NAMI Pharma Marketing Blog Grassley
View PDF of blog article here
Similar Posts
Grassley Probe: Pharma Provides 81% of NAMI Income
The $$$ amounts–one might call them, "fees for services rendered"–reveal the truth about who wields the greatest influence on NAMI policies–and whose interests are being served by NAMI.
Infomail Archive, 2005
Infomail 2005 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Subscribe to the AHRP infomail list Dec 16: Drugs, Devices & Doctors – NYT Paul Krugman Dec 11: Scientific Fraud & Corruption on Both sides of Atlantic: Merck / Proctor & Gamble Dec 11: Gov Accountability…
Antibiotic Ketek Trial in Children
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
Complaint to FDA: Pfizer Failed to Disclose Zoloft Suicide Risk in NYT Adverstisement
Complaint to FDA: Pfizer Failed to Disclose Zoloft Suicide Risk in NYT Adverstisement Mon, 1 Nov 2004 ALLIANCE FOR HUMAN RESEARCH PROTECTION (AHRP) Tel. 212-595-8974 142 West End Ave. Suite 28P Fax: 212-595-9086 New York, NY 10023 www.ahrp.org November 1, 2004 Thomas W. Abrams Director Office…
Infomail Archive 2004
Infomail 2004 News Stories on Human Research Protection and Commentary by Vera Hassner Sharav Dec 31: FDA to review “missing” drug company documents Dec 30: Family of Woman Killed by AIDS Drug Test Sues Doctors, Manufacturer Dec 30: Doctors, Too, Ask: Is This Drug Right? Dec 29: Bill would shield…
British Rethinking Rules After Ill-Fated Drug Trial_NYT
A front page report in The New York Times provides additonal information about the catastrophic TGN1412 medical experiment in which 6 previously healthy volunteers were intravenously injected with monoclonal antibody in a highly risky procedure.